MedTrace Logo

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

NCT06075810 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2024-12-12

No results posted yet for this study

Summary

A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.

Conditions

Interventions

DRUG

MBQ-167

MBQ-167, an inhibitor of Rho GTPases Rac and Cdc42

Sponsors & Collaborators

  • Congressionally Directed Medical Research Programs

    collaborator FED

  • MBQ Pharma

    lead INDUSTRY

Principal Investigators

  • Neil Sankar, MD · CMO, MBQ Pharma

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-09
Primary Completion
2025-10-01
Completion
2025-10-31
FDA Drug
Yes

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06075810 on ClinicalTrials.gov